Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model

Journal of Chemotherapy

Volumn 11, Issue 1, 1999, Pages 34-39

  Ghannoum, M A ^a,b   Okogbule Wonodi, I ^c   Bhat, N ^c   Sanati, H ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Amphotericin B; Candida krusei; Fluconazole; Neutropenic guinea pig; Triazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CANDIDA KRUSEI; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FUNGEMIA; FUNGICIDAL ACTIVITY; GUINEA PIG; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION;

EID: 0033047452     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.1.34     Document Type: Article

References (32)

1. 1 Castellani A. Observations on the fungi found in tropical bronchomycosis. Lancet 1912; 1: 13-15.
2. 2 Hurley R, Winner HI. Pathogenicity in the genus Candida. Dermatol Int 1966; 5: 151-153.
3. 3 Odds FC. Candida and candidosis, 2nd edn. London, Bailliere, Tindall 1988.
4. 4 Samaranayake YH, Samaranayake LP. Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. Med Microbiol 1994; 41: 295-310.
5. 5 Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital; changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1998; 57: 646-655.
6. 6 Jacobs MI, Magid MS, Jarowski CI. Disseminated candidiasis. Newer approaches to early recognition and treatment. Arch Dermatol 1980; 116: 1277-1279.
7. 7 Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused by Candida Krusei. J Clin Microbiol 1986; 24: 581-584.
8. 8 Myerowitz RL, Pazin GJ, Allen CM. Disseminated candidiasis. Changes in incidence, underlying diseases, and pathology. Am J Clin Pathol 1977; 68: 29-38.
9. 9 Rose HD, Varkey B. Deep mycotic infection in the hospitalized adult: a study of 123 patients. Medicine 1975; 54: 499-507.
10. 10 Sanford GR, Merz WG, Wingard JR. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142: 503-509.
11. 11 Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
12. 12 Young RC, Bennett JE, Geelhoed GW, Levine AS. Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med 1974; 80: 605-612.
13. 13 Akova M, Akalin HE, Uzum O, Gur D. Emergence of Candida krusei infections after therapy with oropharyngeal candidiasis with fluconazole [letter]. Eur J Clin Microbiol Infect Dis 1991; 10: 598-599.
14. 14 Akova M, Akalin HE, Uzum O, et al. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer factors influencing the outcome. Clin Infect Dis 1994; 18: 298-304.
15. 15 Goldman M, Pottage JC, Weaver DC. Candida krusei fungemia: report of 4 cases and review of the literature. Medicine (Baltimore) 1993; 72: 143-150.
16. 16 Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22(suppl 2): 89-94.
17. 17 Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5 year period. Antimicrob Agents Chemother 1994; 38: 1422-1424.
18. 18 Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomized multi center trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39: 40-44.
19. 19 Iwen PC, Kelly DM, Reed EC, Henrichs SH. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 1995; 20: 342-347.
20. 20 Hitchcock CA, Pye GW, Oliver GP, Troke PF. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections; antifungal activity and selectivity in vitro. Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 1995: Abstr #F72, p. 125.
21. 21 Jezequel SG, Clark M, Cole S, Evans KE, Wastall P. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pre-clinical pharmacokinetics. Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 1995 Abstr. #F76.
22. 22 Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41: 13-16.
23. 23 Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997; 41: 1840-1842.
24. 24 Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41: 2492-2496.
25. 25 Fratti RA, Belanger PH, Sanati H, Ghannoum MA. The effect of the new triazole, voriconazole, on the interactions among Candida albicans, Candida krusei and endothelial cells. J Chemother 1996; 10: 7-16.
26. 26 National Committee for Clinical Laboratory Standards. Reference Method for broth dilution antifungal susceptibility testing of yeast; approved standard, M27 A. National Committee for Clinical Laboratory Standards, Wayne, Pa 1997.
27. 27 Morace GS, Mansura S, Dettori G. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Chemotherapy (Basel) 1991; 37: 23-31.
28. 28 McQuillen D, Zingman B, Meunier F, Levitz S. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 1992; 14: 472-478.
29. 29 Thomalla JV, Steidle CP, Leapman SB, Filo RS. Ureteral obstruction of a renal allograft secondary to Candida krusei. Transplant Proc 1988; 3: 551-554.
30. 30 Anaissie E, Hachem R, Caesar K, Tin U, Stephens LC, and Bodey GP. Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity. Infect Immun 1993; 61: 1268-1271.
31. 31 Karyotakis NC, Anaissie EJ, Hachem R, Dignani MC, Samonis G. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infect Dis 1993; 168: 1311-1313.
32. 32 Fisher MA, Shen SH, Haddad J, Tarry WF. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 1989; 33: 1443-1446.